Sepsis Clinical Trial
— PhyCordPremOfficial title:
Prospective Unblinded Randomized Controlled Study Assessing the Physiologically Based Cord Clamping on Ventilation Duration in Moderate and Late Preterm
Before birth, the baby's lungs are filled with fluid and babies do not use the lungs to breathe, as the oxygen comes from the placenta. As delivery approaches, the lungs begin to absorb the fluid. After vaginal delivery, the umbilical cord is clamped and cut after a delay that allows some of the blood in the umbilical cord and placenta to flow back into the baby. Meanwhile, as the baby breathes for the first time, the lungs fill with air and more fluid is pushed out. However, it does not always work out that way. A baby born prematurely may have breathing problems because of extra fluid staying in the lungs related to the immaturity of the lung structure. Thus, the baby must breathe quicker and harder to get enough oxygen enter into the lungs. The newborn is separated from the mother to provide emergency respiratory support. Although the baby is usually getting better within one or two days, the treatment requires close monitoring, breathing help, and nutritional help as the baby is too tired to suck and swallow milk. Sometimes, the baby cannot recover well and show greater trouble breathing needing intensive care. This further separates the mother and her baby. A possible mean to help the baby to adapt better after a premature birth while staying close to the mother is to delay cord clamping when efficient breathing is established, either spontaneously or after receiving breathing help at birth. In this study, we intend to test this procedure in moderate or late preterm infants and see whether the technique helps the baby to better adapt after birth and to better initiate a deep bond with the mother.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | July 2026 |
Est. primary completion date | January 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 32 Weeks to 36 Weeks |
Eligibility | Inclusion Criteria: Pregnant women followed-up in Brugmann University Hospital will be eligible to participate if: - The delivery takes place between 32 0/7 and 36 6/7 weeks of gestation - They carry singletons Exclusion Criteria: - Fetal anomalies including congenital malformations, anemia, and growth restriction with abnormal Dopplers. - Abnormal placentation such as placenta previa. - Signs of fetal distress necessitating an emergency cesarean section. - Maternal health issue including severe anemia (defined as hemoglobin level < 7 g/dL), preeclampsia, and bleeding disorders. - Maternal refusal of the use of blood products. - General anesthesia for cesarian section. - Planned cord blood banking. - Total language barrier without possibility of translation |
Country | Name | City | State |
---|---|---|---|
Belgium | CHU Brugmann | Brussels | |
Belgium | Hôpital Universitaire Des Enfants Reine Fabiola | Brussels |
Lead Sponsor | Collaborator |
---|---|
Queen Fabiola Children's University Hospital | Ars Statistica, Fonds IRIS-Recherche, The Belgian Kids Fund |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration of non-invasive or invasive respiratory support. | from Birth to 28 days of life | ||
Secondary | Rate of neonatal mortality | within 28 days of delivery | ||
Secondary | Rate of neonatal resuscitation | Neonatal resuscitation is defined as the use of a T-piece resuscitator for continuous airway positive pressure or intermittent positive pressure (with or without oxygen supplementation). | within first 10 minutes of life | |
Secondary | Rate of neonatal respiratory morbidity | Neonatal respiratory morbidity includes respiratory distress syndrome, transient tachypnea of the newborn, air leak syndrome, and respiratory distress syndrome. | from Birth to 28 days of life | |
Secondary | Number of admission to the NICU or special care baby unit | within first 72 hours of life | ||
Secondary | Length of hospitalization | Up to 8 weeks post delivery | ||
Secondary | Gestational age corrected at discharge | Up to 8 weeks post delivery | ||
Secondary | Changes in physiological variables during neonatal transition | physiological variables includes the timing of the first breath/cry, measurements of parameters during the first 10 minutes of life (i.e., preductal oxygen saturation by pulse oximetry, respiratory rate, heart rate, and temperature), umbilical cord venous hemoglobin and gases, as well as Apgar scores at 1, 5, and 10 minutes. | Within first 10 minutes of life | |
Secondary | Early neonatal parameters | Early neonatal parameters includes body temperature (at 1, 2 and 3 hours of life) and body weight. | within first 24 hours of life | |
Secondary | Hemoglobin level | in g/dl | At 48 hours of life | |
Secondary | Bilirubin level | in mg/dl | At 48 hours of life | |
Secondary | Occurrence of Neonatal adverse events | Adverse events include hypoglycemia (glycemia <47 mg/dl), sepsis (positive blood culture), intraventricular hemorrhage, and the need for phototherapy | Within first 72hours of life | |
Secondary | Biological markers of oxidative stress | immediately after cord clamping | ||
Secondary | Maternal perioperative parameters | Maternal perioperative parameters include total surgical time, intraoperative intravenous fluid volume, intraoperative blood loss, uterotonic administration | up to 3 hours post delivery | |
Secondary | Maternal postoperative hemoglobin level | in g/dl | At day 1 post delivery | |
Secondary | Number of maternal adverse events | Maternal adverse events include death, blood transfusion, postpartum hemorrhage, hysterectomy, admission in the Intensive Care Unit, wound seroma, and wound cellulitis | within first 2 weeks after delivery | |
Secondary | Maternal-infant bonding | Parameters of mother-infant bonding include breastfeeding (Yes/No) | At 2 weeks of life | |
Secondary | Maternal-infant bonding | Parameters of mother-infant bonding include maternal depression measured by the Edinburgh Postnatal Depression Scale (EPDS) - score min = 0, score max = 30, higher score = worse outcome. | At 2 weeks of life | |
Secondary | Maternal-infant bonding | Parameters of mother-infant bonding include maternal depression measured by the Maternal Infant Bonding Scale (MIBS) - score min = 0, score max = 24, higher score = worse outcome | At 2 weeks of life | |
Secondary | Rate of Maternal-infant bonding | Parameters of mother-infant bonding include breastfeeding (Yes/No) | At one month of life | |
Secondary | Rate of Maternal-infant bonding | Parameters of mother-infant bonding include maternal depression measured by the Edinburgh Postnatal Depression Scale (EPDS) - score min = 0, score max = 30, higher score = worse outcome. | At one month of life | |
Secondary | Rate of Maternal-infant bonding | Parameters of mother-infant bonding include maternal depression measured the Maternal Infant Bonding Scale (MIBS) - score min = 0, score max = 24, higher score = worse outcome | At one month of life | |
Secondary | Maternal-infant bonding | Brazelton Neonatal Behavioral Assessment Scale (NBAS) - score min = 1, score max = 6, higher score = better outcome | At 42 weeks of corrected age | |
Secondary | Parental satisfaction survey | At 42 weeks of corrected age | ||
Secondary | Child development assessment | The child development assessment is done using the Bayley scale IV - score min = 1 , score max = 19, higher score = better outcome | At 6 months of corrected age | |
Secondary | Success of PBCC | measured by the percentage of neonates in whom the procedure will be achieved without issue, identification of failed PBCC, and duration of stabilization with PBCC (defined as spontaneous breathing, heart rate (HR) >100 bpm, oxygen saturation by pulse oximetry (SpO2 ) = 85% with inspired oxygen fraction < 0.4). | within first 10 minutes of life |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |